Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohnʼs disease
Inflammatory Bowel Diseases2008Vol. 14(10), pp. 1392–1398
Citations Over TimeTop 10% of 2008 papers
Taina Sipponen, Erkki Savilahti, Päivi Kärkkäinen, Kaija‐Leena Kolho, Hannu Nuutinen, Ulla Turunen, Martti Färkkilâ
Abstract
Compared to pretreatment values, concentrations of fecal calprotectin and lactoferrin after the anti-TNF-alpha treatment were significantly lower. During anti-TNF-alpha therapy these fecal neutrophil-derived proteins may thus be useful surrogate markers for mucosal healing.
Related Papers
- → Multifunctional Iron Bound Lactoferrin and Nanomedicinal Approaches to Enhance Its Bioactive Functions(2015)130 cited
- → Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease(2009)118 cited
- → Are calprotectin and lactoferrin equivalent screening tests for inflammatory bowel disease?(2020)5 cited
- → Rapid radiometric assay used to assess lactoferrin in granulocytes.(1985)10 cited
- → Lactoferrin(1995)